EyePoint Pharmaceuticals, Inc.
EYPT
$14.52
$0.836.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -81.89% | -78.19% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -81.89% | -78.19% | |||
| Cost of Revenue | -13.15% | -6.44% | |||
| Gross Profit | 5.72% | -45.23% | |||
| SG&A Expenses | 20.30% | -13.24% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.76% | -7.82% | |||
| Operating Income | 0.32% | -27.42% | |||
| Income Before Tax | -0.67% | -31.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -0.51% | -31.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.51% | -31.49% | |||
| EBIT | 0.32% | -27.42% | |||
| EBITDA | 0.39% | -27.61% | |||
| EPS Basic | -0.18% | -31.18% | |||
| Normalized Basic EPS | -0.32% | -30.97% | |||
| EPS Diluted | -0.18% | -31.18% | |||
| Normalized Diluted EPS | -0.32% | -30.97% | |||
| Average Basic Shares Outstanding | 0.35% | 0.23% | |||
| Average Diluted Shares Outstanding | 0.35% | 0.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||